(5-chloro-2-fluorophenyl)isobutylamine | 1156335-36-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (5-chloro-2-fluorophenyl)isobutylamine
• 英文别名: 5-chloro-2-fluoro-N-(2-methylpropyl)aniline
• CAS: 1156335-36-2
• 化学式: C₁₀H₁₃ClFN
• 分子量: 201.671
• InChiKey: VRHHICOHWCCEDC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• SULFONAMIDE COMPOUNDS AND THEIR USE IN THE MODULATION RETINOID-RELATED ORPHAN RECEPTOR
  申请人：Glaxo Group Limited

  公开号：US20140243362A1

  公开（公告）日：2014-08-28

  The present invention is directed to novel retinoid-related orphan receptor gamma (RORγ) modulators of formula (I), processes for their preparation, pharmaceutical compositions containing these modulators, and their use in the treatment of inflammatory, metabolic and autoimmune diseases mediated by RORγ wherein R 1 to R 7 are as defined in claim 35.

  本发明涉及一种新型的与视黄醇相关孤儿受体γ（RORγ）调节剂，其化学式为（I），以及用于制备这些调节剂的方法，含有这些调节剂的药物组合物，以及它们在治疗由RORγ介导的炎症、代谢和自身免疫疾病中的应用，其中R1至R7如权利要求35所定义。
• [EN] SULFONAMIDE COMPOUNDS AND THEIR USE IN THE MODULATION RETINOID - RELATED ORPHAN RECEPTOR<br/>[FR] COMPOSÉS DE SULFONAMIDE ET LEUR UTILISATION DANS LA MODULATION DU RÉCEPTEUR ORPHELIN APPARENTÉ AU RÉCEPTEUR DES RÉTINOÏDES
  申请人：GLAXO GROUP LTD

  公开号：WO2013045431A1

  公开（公告）日：2013-04-04

  The present invention is directed to novel retinoid-related orphan receptor gamma (RORy) modulators of formula (I), processes for their preparation, pharmaceutical compositions containing these modulators, and their use in the treatment of inflammatory, metabolic and autoimmune diseases mediated by RORy wherein R1 to R7 are as defined in claim 1.

  本发明涉及一种新型的与视黄醇相关孤儿受体γ（RORγ）调节剂，其化学式为（I），以及制备这些调节剂的方法、含有这些调节剂的药物组合物，以及它们在治疗由RORγ介导的炎症性、代谢性和自身免疫性疾病中的应用，其中R1至R7如权利要求1所定义。
• INDAZOLE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T))
  申请人：GALDERMA RESEARCH & DEVELOPMENT

  公开号：US20170342062A1

  公开（公告）日：2017-11-30

  Indazole sulfonamide derivatives of formula (I), the pharmaceutically acceptable addition salts thereof, the hydrates and/or solvates thereof, and the use of same as inverse agonists of retinoid-related orphan receptor gamma RORγt are described. Pharmaceutical compositions including such compounds, as well as the use thereof for the topical and/or oral treatment of RORγt receptor-mediated inflammatory diseases, in particular acne, psoriasis and/or atopic dermatitis are also described.

  本发明涉及式(I)的吲唑磺胺衍生物，其药学上可接受的加盐物，其水合物和/或溶剂合物，以及将其用作视黄醇相关孤儿受体伽玛RORγt的逆向激动剂的用途。还描述了包括这些化合物的药物组合物，以及将其用于治疗RORγt受体介导的炎症性疾病，特别是痤疮、银屑病和/或特应性皮炎的局部和/或口服治疗。
• Indazole sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR γ (T))
  申请人：GALDERMA RESEARCH & DEVELOPMENT

  公开号：US10246440B2

  公开（公告）日：2019-04-02

  Indazole sulfonamide derivatives of formula (I), the pharmaceutically acceptable addition salts thereof, the hydrates and/or solvates thereof, and the use of same as inverse agonists of retinoid-related orphan receptor gamma RORγt are described. Pharmaceutical compositions including such compounds, as well as the use thereof for the topical and/or oral treatment of RORγt receptor-mediated inflammatory diseases, in particular acne, psoriasis and/or atopic dermatitis are also described.

  本发明描述了式(I)的吲唑磺酰胺衍生物、其药学上可接受的加成盐、其水合物和/或溶剂，以及其作为维甲酸相关孤儿受体γ RORγt的逆激动剂的用途。 此外，还介绍了包括此类化合物的药物组合物，以及将其用于局部和/或口服治疗 RORγt 受体介导的炎症性疾病，特别是痤疮、牛皮癣和/或特应性皮炎的方法。
• Indazole sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR gamma (T))
  申请人：GALDERMA RESEARCH & DEVELOPMENT

  公开号：US10752617B2

  公开（公告）日：2020-08-25

  Indazole sulfonamide derivatives of formula (I), the pharmaceutically acceptable addition salts thereof, the hydrates and/or solvates thereof, and the use of same as inverse agonists of retinoid-related orphan receptor gamma RORγt are described. Pharmaceutical compositions including such compounds, as well as the use thereof for the topical and/or oral treatment of RORγt receptor-mediated inflammatory diseases, in particular acne, psoriasis and/or atopic dermatitis are also described.

  本发明描述了式(I)的吲唑磺酰胺衍生物、其药学上可接受的加成盐、其水合物和/或溶剂，以及其作为维甲酸相关孤儿受体γ RORγt的逆激动剂的用途。此外，还介绍了包括此类化合物的药物组合物，以及将其用于局部和/或口服治疗 RORγt 受体介导的炎症性疾病，特别是痤疮、牛皮癣和/或特应性皮炎的方法。